Infrastructure specialist Construction Partners (NASDAQ: ROAD) is poised to release its fourth-quarter results Thursday morning. With mixed performance last quarter and shifting analyst expectations, here’s a breakdown of what investors should watch.
AGCO is set to report its fourth-quarter earnings before the bell on Thursday, with analysts forecasting a year-over-year revenue decline. Investors will be watching closely for signs of resilience in the agricultural equipment sector.
As Haemonetics prepares to report its fiscal fourth-quarter results, investors are watching for signs of stabilization after a period of declining revenues and a significant stock price drop. The report will shed light on the company's performance amid a mixed landscape for medical equipment peers.
The iconic fashion house Ralph Lauren (NYSE:RL) is scheduled to release its fourth-quarter financial results before Thursday's market open. Analysts project a slowdown in revenue growth compared to last year's strong performance, setting the stage for a closely watched report.
As QuinStreet prepares to report its fiscal fourth-quarter results, investors are watching for signs of stability after a period of significant stock price pressure. Analysts anticipate a year-over-year revenue dip, setting the stage for a critical update on the company's trajectory.
All eyes are on Ladder Capital (LADR) as it prepares to release its quarterly results amid a challenging commercial real estate landscape and a track record of recent misses.
Former Brevard County elementary school principal Elizabeth Hill-Brodigan received probation after pleading no contest to charges related to a massive underage drinking party at her home, a case that has sparked debate over accountability for educators.
Minnesota's top corrections official voices frustration over vague federal plans to scale back a controversial immigration operation, citing eroded trust and demanding transparency in the investigation of two agent-involved shootings.
After years of declining share prices, Pfizer is banking on a pipeline packed with over 20 pivotal Phase 3 trial launches this year to reignite growth and investor confidence.
Amid a sharp sell-off in growth-oriented sectors, risk-averse capital flowed into stable, income-generating giants on Tuesday, highlighting a broader market rotation.
Netflix's proposed acquisition of Warner Bros. Discovery, valued at $82.7 billion, is undergoing intense antitrust scrutiny. U.S. regulators and lawmakers are examining the deal's potential impact on streaming competition, content diversity, and the future of live sports broadcasting, including the Olympics.
Amid market volatility, a bullish case emerges for Procter & Gamble (PG), highlighting its resilient brand portfolio, consistent capital returns, and potential strategic shifts under new leadership.
Despite posting explosive revenue and earnings growth, UP Fintech Holding Limited trades at a significant discount. Analysts point to its successful pivot to Singapore and Hong Kong, robust balance sheet, and a potential 87% upside as catalysts for a major re-rating.
As Honeywell International advances its plan to separate its Aerospace unit, analysts see a classic value-unlocking story. Beyond the spin-offs, the conglomerate's significant stake in quantum computing firm Quantinuum adds a layer of high-tech optionality to its steady industrial core.
AMETEK caps a strong 2025 with record sales and earnings, bolstered by the acquisition of LKC Technologies. While the company forecasts continued growth into 2026, analysts debate whether its premium valuation is justified amidst a broader market rally.
Senate Minority Leader Mitch McConnell was admitted to a hospital Monday evening for observation after reporting flu-like symptoms. His office states his condition is stable and a return to Capitol Hill is anticipated.
TransMedics Group, Inc. (TMDX), a pioneer in portable organ perfusion technology, is drawing significant investor interest. With its shift to a recurring revenue model and FDA approvals expanding its market, the company presents a compelling growth story in the medtech sector, despite a premium valuation.
As Teva Pharmaceutical shifts focus from its legacy generics business to a promising innovative pipeline, its experimental drug Duvakitug emerges as a potential valuation catalyst. We examine the bull case, the competitive landscape, and what it means for investors.
Penumbra, Inc. (NYSE: PEN), a dominant force in thrombectomy devices, has seen its stock retreat amid a broad market shift away from healthcare. With fundamentals intact and a debt-free balance sheet, analysts see the dip as a buying opportunity ahead of key catalysts.
Despite being battered by market pessimism, Polestar Automotive is drawing attention from contrarian investors who see its deep ties to automotive giant Geely as a potential lifeline. With billions in revenue and a powerful backer, the question is whether this EV brand can navigate its cash burn and tariff challenges.
